Adma Biologics Inc Expected To Post A Loss Of 8 Cents A Share: Earnings Preview

ADMA Biologics

09/08/2022 24:42

* ADMA Biologics Inc  ADMA.OQ   ADMA.O  is expected to show
a rise
in quarterly revenue when it reports  results on August 10. 
    * The Ramsey New Jersey-based  company is expected to report
 a
78.4% increase in revenue to $31.812 million from $17.83 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ADMA Biologics Inc
is for
a loss of 8 cents per share. For the same quarter last year, the
company reported a loss of 14 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADMA
Biologics
Inc is $4.75​, above​ its last closing price of $2.07. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.08       -0.08      -0.10     Missed  -17.6
 Dec. 31 2022              -0.09      -0.09     Met     3.6
 Sep. 30 2021  -0.14       -0.14      -0.13     Beat    9.7​
 Jun. 30 2021  -0.13       -0.15      -0.14     Beat    6.7
 ​​Mar.        -0.16       -0.17      -0.16     Beat    3.6
 31 2021                                                
 Dec. 31 2020  -0.17       -0.16      -0.20     Missed  -24.1​
 Sep. 30 2020  -0.18       -0.19      -0.19     Met     -1.8
 Jun. 30 2020  -0.15       -0.16      -0.23     Missed  -46.5
 This summary was machine generated August 8 at 23:42 GMT.  All
figures in US dollars  unless otherwise stated